US FDA's Office Of New Drugs Reorganization Approved, But Not Happening Overnight
Executive Summary
OND will grow to eight offices and 27 clinical divisions, which is slightly different than an early proposal.
You may also be interested in...
FDA’s Cell, Gene Therapy Office Head Wilson Bryan Set To Retire
OTAT Director Bryan, who has worked at the FDA for more than 20 years, will depart by the end of March as the agency’s cell and gene therapy operations are poised for a major overhaul and a large number of new hires.
US FDA Wants Assessment Of New Drug Review ‘Culture’ Amid Modernization, Other Changes
The New Drug Review Program is seeking a contractor to survey employees on the impact of team culture on performance and overall effectiveness.
BsUFA Suggestions From Sponsors Sound Easy, But Changes May Be Difficult For US FDA
Biosimilar sponsors want meeting and assessment best practices implemented across divisions, but the FDA says that may be difficult and time-consuming.